Sana Biotechnology Inc Ordinary Shares SANA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $3.85
- Day Range
- $3.56–3.78
- 52-Week Range
- $2.61–6.55
- Bid/Ask
- $3.64 / $3.85
- Shares Outstanding
- 278.29M
- Market Cap
- $1.01B
- Volume/Avg
- 2M / 4M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 142
- Website
- https://www.sana.com
Valuation
|
Metric
|
SANA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 8.70 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SANA
|
|---|---|
Quick Ratio | 1.17 |
Current Ratio | 1.29 |
Interest Coverage | — |
Quick Ratio
SANA
Profitability
|
Metric
|
SANA
|
|---|---|
Return on Assets (Normalized) | −42.61% |
Return on Equity (Normalized) | −107.35% |
Return on Invested Capital (Normalized) | −72.56% |
Return on Assets
SANA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@SVpz^ | LOCK|b&?q | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Fd>>!%# | LOCK|>v&!? | $70B | |||
| argenx SE ADR
ARGX
| LOCK|PRvBXyK | LOCK|ff | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|bb$Qp## | LOCK|!&CtX | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@Vw<KRZ | LOCK|mY | $36B | |||
| Moderna Inc
MRNA
| LOCK|Wl&?FQ | LOCK|^by | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|m<^V@d$ | LOCK|Jh^> | $25B | |||
| Incyte Corp
INCY
| LOCK|><!!w! | LOCK|F@z | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|X^NcBmK | LOCK|YT | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|!^>CKR | LOCK|zGg | $17B |
United States